{"id":952165,"date":"2026-04-16T12:23:49","date_gmt":"2026-04-16T16:23:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026\/"},"modified":"2026-04-16T12:23:49","modified_gmt":"2026-04-16T16:23:49","slug":"myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026\/","title":{"rendered":"Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026"},"content":{"rendered":"
\n

SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.<\/a> (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research<\/a> (AACR) Annual Meeting 2026.<\/p>\n

“AACR is one of the premier forums for oncology research, and we are excited to share the depth of work underway across our MRD and hereditary cancer programs, including two podium presentations demonstrating the exceptional performance of Precise MRD, Myriad\u2019s tumor-informed, ultrasensitive MRD assay,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics.<\/p>\n

The company will share new results from the MONITOR-Breast study, a prospective, multi-center clinical trial evaluating the performance of Precise MRDTM<\/sup> in breast cancer across all phases of the treatment journey. The data will be shared in a podium presentation on Monday, April 20, 2026 by Dr. Julia Foldi, MD, PhD, University of Pittsburgh Medical Center Hillman Cancer Center. These results expand on the study’s early insights presented at the San Antonio Breast Cancer Symposium in December 2025, including results from a large cohort of patients receiving neoadjuvant therapy with frequent MRD assessment, providing the first high-temporal resolution characterization of ctDNA dynamics in all breast cancer subtypes during neoadjuvant treatment.<\/p>\n

“Breast cancer treatment has evolved significantly, but clinicians still face real challenges in assessing how well a patient is responding to therapy in the neoadjuvant setting,” said Dr. Foldi. “The data being presented at AACR reveal distinct response patterns that are associated with pathological response and demonstrate that frequent, ultrasensitive MRD testing can provide personalized information about treatment effectiveness. MONITOR-Breast is generating important clinical evidence for Precise MRD in breast cancer that could help oncologists personalize treatment decisions for their patients.”<\/p>\n

Additionally, Dr. Ranjan Upadhyay from The University of Texas MD Anderson Cancer Center will present the results of a phase II clinical trial. Together, these results from clinical trials continue to build and expand the evidence supporting the performance of the Precise MRD test in breast cancer treatment and surveillance.<\/p>\n

The following abstracts will be presented at the American Association for Cancer Research Annual Meeting<\/a> on April 17-22, 2026, at the San Diego Convention Center in San Diego.<\/p>\n

\n Myriad Genetics Presentations<\/strong>
\n
\n Session CTMS04 – Focus on ctDNA<\/em>
\n
\n Early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using an ultrasensitive MRD assay<\/em>
\n
\n Podium<\/strong>; Abstract Presentation Number: CT171
Mon., April 20 \u2013 2:50 – 3:00 pm, Hall H – Ground Level – Convention Center
Presenter: Julia Foldi, MD, PhD, University of Pittsburgh Medical Center<\/p>\n

\n Session CTMS04 – Focus on ctDNA<\/em>
\n
\n A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: Circulating biomarkers and molecular correlates of clinical outcomes<\/em>
\n
\n Podium<\/strong>; Abstract Presentation Number: CT172
Mon., April 20 \u2013 3:05 – 3:15 pm PST, Hall H – Ground Level – Convention Center
Presenter: Ranjan Upadhyay, MD, PhD, The University of Texas MD Anderson Cancer Center<\/p>\n

\n Liquid Biopsies: Circulating Nucleic Acids 2 <\/em>
\n
\n Analytical validation of an ultra-high sensitivity tumor-informed MRD assay<\/em>
\n
Poster Board Number: 2598
Mon., April 20 \u2013 9:00 am – 12:00 pm PST
Presenter: Ashley Acevedo, PhD, Myriad Genetics<\/p>\n

\n Genetic Epidemiology 1: GxE, GWAS, Polygenic Risk Scores, and Post-GWAS <\/em>
\n
\n Independent validation of polygenic risk scores for overall and triple-negative breast cancer among high-risk African American women<\/em>
\n
Poster Board Number: 3587
Mon., April 20 \u2013 2:00 \u2013 5:00 pm PST
Presenter: Dezheng Huo, PhD, University of Chicago<\/p>\n

\n Liquid Biopsies: Circulating Nucleic Acids 4 <\/em>
\n
\n Fragmentomic analysis of cfDNA WGS at regulatory regions generates gene-level expression-like traits for subtype analysis in breast cancer <\/em>
\n
Poster Board Number: 5313
Tues, April 21 \u2013 9:00 am \u2013 12 pm PST
Presenter: James Davison, PhD, GeneCentric Therapeutics, Inc.<\/p>\n

\n Phase I and Phase II Clinical Trials in Progress <\/em>
\n
\n A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions: Impact of treatment selection, oncologic outcomes, and treatment-related adverse events (PROMPT-Bx)<\/em>
\n
Poster Board Number: 14; Abstract Presentation Number: CT280
Tues., April 21 \u2013 2:00-5:00 pm PST
Presenter: Matthew Schiewer, PhD, Myriad Genetics<\/p>\n

\n Conference Highlights<\/strong>
\n
Myriad will welcome attendees to its booth (#3747) during exhibition hours. Myriad tests to be highlighted at the conference booth include:<\/p>\n